Presented By Michele Cavo at 2016 ASCO Annual Meeting

Slides:



Advertisements
Similar presentations
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Advertisements

1. 2 Lenalidomide in Newly Diagnosed Multiple Myeloma Clinical Update EHA 2010 DR. OUSSAMA JRADI.
Corre J et al. Proc ASH 2014;Abstract 180.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Trials Singh PP et al. Proc ASH 2013;Abstract 407.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.
ASCO 2010 Lenalidomide maintenance after transplantation for myeloma (IFM Study) Authors: Attal et al, ASCO 2010 Abstract:
Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.
Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.
A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.
Proteasome inhibitors in multiple myeloma: 10 years later Philippe Moreau, Paul G. Richardson, Michele Cavo, Robert Z. Orlowski, Jesu´s F. San Miguel,
Controversies in multiple myeloma: Evidence-based update
Presented By Sham Mailankody at 2016 ASCO Annual Meeting
Presented By Lorenz Trumper at 2016 ASCO Annual Meeting
Chen R et al. Proc ASH 2015;Abstract 518.
Palumbo A et al. Proc ASH 2012;Abstract 200.
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
Highlights: Myeloma Oral Session
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
Presented By Luca Malorni at 2017 ASCO Annual Meeting
continued on next slide
KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM CCO Independent Conference Coverage* of the 2016.
Presented By Amrita Krishnan at 2016 ASCO Annual Meeting
Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy
Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Innovations and Issues in Mantle Cell Lymphoma
Attal M et al. Proc ASCO 2010;Abstract 8018.
Selecting Therapy for Relapsed/ Refractory Multiple Myeloma
James R. Berenson, MD Medical & Scientific Director
Multiple Myeloma: Diagnosis and Treatment
How I treat elderly patients with myeloma
Figure 3 Proportion of patients for whom NEDA
Figure 5 Number of AHSCT procedures for
Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.
Palumbo A et al. Proc ASCO 2011;Abstract 8007.
Pharmacist Perspectives on Novel Agents in Multiple Myeloma
Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront.
Presented at EHA2018 Michael Austin
Presented By Praful Ravi at 2016 ASCO Annual Meeting
Approaches in Newly Diagnosed Multiple Myeloma: When and What
Presented By Mathias Rummel at 2016 ASCO Annual Meeting
Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis.
Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes.
Multiple Myeloma in Serologic Complete Remission after Autologous Stem Cell Transplantation: Impact of Bone Marrow Plasma Cell Assessment by Conventional.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Managing Your Patient’s Maintenance Therapy for Multiple Myeloma
Presented By Steven Park at 2016 ASCO Annual Meeting
Biology of Blood and Marrow Transplantation
On the Cusp: New Approaches for Multiple Myeloma
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma  Christopher Parrish, Amin Rahemtulla, Jim.
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma 
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma  Dharshan Sivaraj, Michael.
Boccadoro M et al. Proc ASCO 2011;Abstract 8020.
Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant  Ahmad Hatem Mattour,
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival  Victor H. Jimenez-Zepeda,
Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy 
Presented By Joshua Richter at 2016 ASCO Annual Meeting
Presented By Andrew Evens at 2016 ASCO Annual Meeting
High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis.
by Lapo Alinari, and Kristie A. Blum
624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results    Molecular.
Presentation transcript:

Presented By Michele Cavo at 2016 ASCO Annual Meeting Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for Multiple Myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial) Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Background Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Background. 2 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 4 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 5 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 6 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 7 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 8 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 9 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 10 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 11 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 12 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 13 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 14 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 15 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 16 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 17 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 18 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 19 Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Michele Cavo at 2016 ASCO Annual Meeting Slide 20 Presented By Michele Cavo at 2016 ASCO Annual Meeting